Yamaguchi Satoshi, Nadoyama Nokanan, Kinjo Kazushi, Yagi Nobumori, Ishimori Hiroshi, Shimabukuro Michio
Department of Diabetes, Endocrinology and Metabolism, School of Medicine, Fukushima Medical University, Fukushima, JPN.
Department of Cardiology, Nakagami Hospital, Okinawa, JPN.
Cureus. 2023 Jun 18;15(6):e40609. doi: 10.7759/cureus.40609. eCollection 2023 Jun.
Depressed cardiac systolic function in hemodialysis patients occurs for a variety of reasons and is a clinical problem. Beta-blockers are a key drug in the treatment of heart failure; however, hypotension may occur, particularly in dialysis patients, thereby complicating dialysis. Ivabradine has the unique property of a negative chronotropic effect only, without the negative inotropic effect. A 55-year-old woman who underwent dialysis presented with dyspnea and fatigue even at rest due to low cardiac systolic function. The left ventricular ejection fraction (LVEF) was 30%. Medications for heart failure, such as carvedilol and enalapril, were initiated; however, they were discontinued owing to intradialytic hypotension. Subsequently, her heart rate increased to over 100 beats per minute (bpm); therefore, we administered 2.5 mg of ivabradine before beta-blockers, which reduced her heart rate by approximately 30 bpm without a significant blood pressure decrease. Moreover, her blood pressure stabilized during dialysis. After two weeks, we added 1.25 mg of bisoprolol and adjusted the dose to 0.625 mg. After seven months of treatment with 2.5 mg ivabradine and 0.625 mg bisoprolol, systolic cardiac function significantly improved to 70% of LVEF. Prioritizing ivabradine over beta-blockers may not cause intradialytic hypotension; even low doses of ivabradine and bisoprolol were considered effective heart failure therapies.
血液透析患者出现心脏收缩功能减退的原因多种多样,这是一个临床问题。β受体阻滞剂是治疗心力衰竭的关键药物;然而,可能会发生低血压,尤其是在透析患者中,从而使透析变得复杂。伊伐布雷定具有仅产生负性变时作用而无负性肌力作用的独特特性。一名接受透析的55岁女性因心脏收缩功能低下,即使在休息时也出现呼吸困难和疲劳。左心室射血分数(LVEF)为30%。开始使用心力衰竭药物,如卡维地洛和依那普利;然而,由于透析期间低血压,这些药物被停用。随后,她的心率增加到每分钟100次以上(bpm);因此,我们在使用β受体阻滞剂之前给予2.5mg伊伐布雷定,这使她的心率降低了约30bpm,且血压没有明显下降。此外,她在透析期间血压稳定。两周后,我们添加了1.25mg比索洛尔,并将剂量调整为0.625mg。在用2.5mg伊伐布雷定和0.625mg比索洛尔治疗七个月后,心脏收缩功能显著改善,LVEF达到70%。优先使用伊伐布雷定而非β受体阻滞剂可能不会导致透析期间低血压;即使是低剂量的伊伐布雷定和比索洛尔也被认为是有效的心力衰竭治疗方法。